Dyne Therapeutics, Inc. (Nasdaq: DYN) has announced a proposed underwritten public offering of $300 million in shares of its common stock, according to a press release from the clinical-stage neuromuscular disease company.

The company also intends to grant underwriters a 30-day option to purchase up to an additional $45 million in shares. All shares in the proposed offering are to be sold by Dyne.

Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are acting as joint book-running managers for the offering. Jones is acting as lead manager.

The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission on March 5, 2024, which became automatically effective upon filing.

The completion of the offering remains subject to market and other conditions, with no assurance provided as to whether or when it may be completed, or as to its final size or terms.

Dyne is advancing clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy, as well as preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.